Andrea Duchini, M.D., F.A.C.P.
Associate Professor, Division of Gastroenterology and Hepatology
Andrea Duchini, M.D., F.A.C.P.
Associate Professor
Director of Hepatology
Medical Director of Liver Transplantation
Division of Gastroenterology & Hepatology
Department of Internal Medicine
University of Texas Medical Branch
301 University Blvd.
Galveston, TX 77555-0764
Phone: 409.772.1501
anduchin@utmb.edu
Biosketch
Dr. Andrea Duchini is currently the Director of Hepatology and Medical Director of Liver Transplantation in the Division of Gastroenterology and Hepatology, Department of Internal Medicine at The University of Texas Medical Branch (UTMB) in Galveston, TX. Dr. Duchini is an Associate Professor of Medicine and Surgery. He also serves as UNOS Primary Physician for the Small Bowel Transplant Program. Prior to his current position at UTMB, Dr. Duchini was the Associate Medical Director of Liver Transplantation, Division of Transplantation, Department of Surgery at the Methodist Hospital, Houston, Texas.
Dr. Duchini received his MD degree with honors in 1988 from the University of Florence, School of Medicine, Italy, where he also completed a Post-Graduate Program in Hepatology. Dr. Duchini completed his Internal Medicine Residency at Baylor College of Medicine, Houston, Texas and his Gastroenterology Fellowship at Scripps Clinic and Research Foundation in La Jolla, California. He subsequently served as faculty at Baylor College of Medicine until 2009 as Assistant Professor of medicine and surgery.
Dr. Duchini became a Fellow with the American College of Physicians in 2009 and is a member of the Texas Society of Gastrointestinal Endoscopy (TSGE), Texas Transplant Society (TTS), International Liver Transplant Society (ILTS), and the American Association for the Study of Liver Diseases (AASLD). He serves on several committees including the UTMB transplant board.
Dr. Duchini is Board Certified in Gastroenterology and Transplant Hepatology.
Research Interests
Dr. Duchini's research interests include different areas of liver diseases and transplantation. In the past he focused his research on vaccinations in solid organ transplant recipients and influenza infection after liver transplant. At the moment he is studying complications of liver transplantation, application of MELD system to liver transplantation outcome, immunosuppresive regimens after transplantation of liver and small bowel and treatment of Hepatitis C. Dr. Duchini has conducted clinical trials in liver diseases since 2000. Currently, he is principal investigator in several clinical trials that are open for enrollment, including therapy of liver cancer, hepatitis C in non-responder, hepatorenal syndrome and thrombocytopenia in cirrhosis. Dr Duchini is currently a member of the Scripps Clinic Liver Consortium which conduct numerous multicenter trials in the US in the field of liver disease.
Clinical Interests
Dr. Duchini's clinical expertise is in liver disease, hepatitis B and C, cirrhosis, liver transplantation and intestinal failure. Dr. Duchini has specific training in endoscopy in patients with liver disease, both for diagnostic and therapeutic control of bleeding. He is available to perform most gastroenterology procedures needed in patients with liver disease, including upper endoscopy, colonoscopy, double balloon enteroscopy and liver biopsy.
Selected Publications
- Cominelli F, Nast CC, Duchini A, M. Lee. Recombinant IL-1 receptor antagonist blocks the proinflammatory activity of endogenous IL-1 in rabbit immune colitis. Gastroenterology, 103:65-71, 1992.
- Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M, P. Gentilini. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 31(9): 456-460, 1993
- Duchini A. The role of CNS endothelial cell activation in the pathogenesis of hepatic encephalopathy. Med Hypoth 46;239-244, 1996.
- Duchini A, Govindarajan S, Santucci M, Zampi G, FM Hofman. Effects of tumor necrosis factor and interleukin-6 on fluid-phase permeability and ammonia diffusion in CNS derived endothelial cells. J Investig Med 44;474-482, 1996.
- Duchini A, Cassaro M, RM Genta. [Helicobacter pylori, gastric pathology and histological diagnosis]. Pathologica 89(6):583-91, 1997.
- Duchini A, Sessoms SL. Gastrointestinal hemorrhage in patients with systemic sclerosis and CREST. Am J Gastroenterol 93(9): 1453-6, 1998.
- Duchini A, Viernes E, Nyberg LM, Hendry RM, PJ Pockros. Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch Intern Med, 160;113-115, 2000.
- Duchini A, Bradley S, Russack V, PJ Pockros. Pulmonary infarction after liver transplant and previous hepatopulmonary syndrome. South Med J, 93(8):823-4, 2000
- Duchini A, Hendry RM, Redfield DC, PJ Pockros. Influenza infection in patients before and after liver transplantation. Liver Transpl, 6(5);531-542, 2000.
- Duchini A, McHutchinson JG, Pockros PJ. LKM-positive autoimmune hepatitis in the Western US; a case-series. Am J Gastroenterol, 95(11):3238-41, 2000.
- Duchini A, Younussi Z, Saven A, Bordin G, Knowles HJ, Pockros PJ. A open-label pilot trial of 2CdA in patients with primary sclerosing cholangitis. J Clin Gastro, 31(4):292-296, 2000
- Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transplantation, 7(4):311-313, 2001
- Duchini A, Brunson ME. Roux-n-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity. Transplantation, 72;156-158, 2001
- Duchini A. Autoimmune hepatitis and interferon-beta for multiple sclerosis. Am J Gastroenterol 97(3):767-768, 2002.
- Duchini A, Redfield DC, McHutchison JG, Brunson ME, Pockros PJ. Aspergillosis in liver transplant recipients; Successful treatment and improved survival using a multistep approach. South Med J 95:897-899, 2002.
- Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison JG, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 97(8):2040-5, 2002.
- Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations in adult solid organ transplant recipients; current recommendations and protocols. Clin Microbiol Rev 16(3);357-363, 2003.
- Julapalli VR, Bray PF, Duchini A. Elevated Factor VIII and Portal Vein Thrombosis. Dig Dis Sci 48(12): 2369-71, 2003.
- Aloia TA, Fahy BN, Fishcer CP, Jones SL, Duchini A, Galati J, Gaber AO, Ghobrial RM, and Base BL. Predicting poor outcome following hepatectomy: analysis of 2313 hepatectomies in the NSQIP database. HPB (Oxford). 11(6): 510-515. September 2009
- Bhardwaj RR, Duchini A. Non-Alcoholic-Steatohepatitis (NASH) in Myotonic Dystrophy; DMPK Gene Mutation, Insulin-Resistance and Development of Steatohepatitis. Case-reports in Gastroenterology, Karger , 2010
- K. Kasturi, A. Duchini. An Unusual Case of Ulcerative Duodenitis, Gastroenterology 2011
The UTMB Center for Global Health Education (CGHE) is dedicated to the training of tomorrow's global health work force to improve health for the people of Texas and around the world. Check out their website for more information on the global health programs and education going on in our department.
Featured Videos
The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.
Currently available protocols are:- CAP - Community Acquired Pneumonia Orderset
- Congestive Heart Failure (CHF)
- Chronic Obstructive Pulmonary Disease (COPD)
- Diabetic Ketoacidosis Adult, ICU
- General Medicine Admission
- Immunodeficiency Flow Panel
- MICU/CCU Admission Order Set
- Oral Analgesic Medicaitons
- Parenteral Opioids
- Sepsis, Adult ICU
All protocols can be found in the EPIC order set section.
The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.
